Ulcerative Colitis

CytoDyn, Inc.

(OTCBB:CYDY) has firmed up the date for its Annual Meeting to be held at 11:00 AM Pacific Time on January 31, 2006 in Studio City (Los Angeles), California.

Shareholders attending will hear a scientific presentation on the status of the development track for Cytolin®, the first targeted immune therapy for treating HIV/AIDS that was shown to significantly decrease viral burden in preliminary clinical studies that completed the Phase 1(a) and Phase 1(b)/Phase 2(a) stages of development.

The differences between this new approach to treating HIV/AIDS and the current drugs will be explained.

Attendees will also be updated on the Company's progress in executing its business plan and will have the opportunity to talk to management.

The CEO's Annual Report may be downloaded from the Company's web site at www.cytodyn.com.

Drug development firm AtheroGenics Inc.

on Monday said it will receive a $50 million payment from AstraZeneca PLC (NYSE:AZN) after regulators cleared a licensing deal between the companies.

AtheroGenics and AstraZeneca have partnered for the worldwide development and co...

Read more...